Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AXSM

Investors Beware of These 3 Pharma Stocks

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug

Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug

Axsome reported strong fourth-quarter sales Tuesday, but AXSM stock tumbled on a setback for the company's Alzheimer's agitation treatment.

Investors Business Daily

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome expects its eight products to generate up to $11.5 billion in peak U.S. sales. AXSM stock zoomed higher Wednesday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.

Axsome and BioXcel issued divergent earnings reports Monday, but BTAI stock reversed an earlier dive and rose alongside AXSM stock.

Investors Business Daily

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling

Teva Pharmaceutical said Monday it plans to make a knockoff of Axsome Therapeutics' new depression treatment, leading AXSM stock to tumble.

Investors Business Daily

Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges

Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.

Investors Business Daily

Better Buy: Axsome Therapeutics vs. Johnson & Johnson

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….

inkl

Read news from The Economist, FT, and more,
with one subscription

Axsome Wins A 60-Year First In Depression; And Shares Catapult 40%

Axsome Wins A 60-Year First In Depression; And Shares Catapult 40%

The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.

Investors Business Daily

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed.

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why

The Food and Drug Administration could be nearing a decision on Axsome Therapeutics' depression treatment, and AXSM stock rocketed Monday.

Investors Business Daily

FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine

FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

A Preview Of Axsome Therapeutics's Earnings

A Preview Of Axsome Therapeutics's Earnings

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Axsome Therapeutics will report an earnings per share (EPS) of $-1.00.

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics (NASDAQ:AXSM) will host a conference call at 08:00 AM ET on May 2, 2022, to discuss Q1 2022 earnings results.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle

Axsome Therapeutics expects the Food and Drug Administration to reject its migraine treatment, leading AXSM stock to crumble on Monday.

Investors Business Daily

Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent

Axsome Therapeutics said Tuesday it agreed to the FDA's requirements for approving its depression drug, and AXSM stock rocketed.

Why Axsome Therapeutics Stock Is Trading Higher

Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).

Axsome Therapeutics: Q4 Earnings Insights

Axsome Therapeutics (NASDAQ:AXSM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Organisations

Food and Drug Administration

Medical Pharmaceuticals

Medical – Pharmaceuticals

Axsome rapeutics

Axsome Therapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play